Drug intelligence / Profile preview

ReS3-T

Development stage: Preclinical
Lead developer: reMYND
Modality: Small Molecules

Overview

**ReS3-T** is an investigational small molecule drug candidate developed by reMYND NV in collaboration with KU Leuven’s Centre for Drug Design and Discovery (CD3). It acts via a novel proprietary target, **Pde6δ** (phosphodiesterase 6 delta), to modulate neuronal activity, demonstrating strong preclinical efficacy in models of therapy-resistant epilepsies, including Dravet syndrome. Accepted into the US NIH NINDS Epilepsy Therapy Screening Program (ETSP) in 2021 for rigorous testing focused on treatment-resistant epilepsies, disease prevention, and modification.[1][2][7]

Targets

PDE6D (Phosphodiesterase 6-delta)

Beyond the preview

Go deeper on ReS3-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ReS3-T.

Explore the full profile